Please use this identifier to cite or link to this item:
metadata.dc.type: Artigo de Periódico
Issue Date: 2004
metadata.dc.creator: KHAYAT, André Salim
GUIMARÃES, Adriana Costa
CARDOSO, Plínio Cerqueira dos Santos
LIMA, Patrícia Danielle Lima de
BAHIA, Marcelo de Oliveira
ANTUNES, Lusânia Maria Greggi
Title: Mutagenicity of hydroxyurea in lymphocytes from patients with sickle cell disease
Citation: KHAYAT, André Salim et al. Mutagenicity of hydroxyurea in lymphocytes from patients with sickle cell disease. Genetics and Molecular Biology, São Paulo, v. 27, n. 1, p. 115-117, 2004. Disponível em: <>. Acesso em: 09 jun 2011. <>.
Abstract: Hydroxyurea is commonly used in the treatment of myeloproliferative diseases and in patients with sickle cell disease (SCD). The use of this antineoplastic agent in patients with SCD is justified because of the drug's ability to increase fetal hemoglobin levels, thereby decreasing the severity of SCD. However, high doses or prolonged treatment with hydroxyurea can be cytotoxic or genotoxic for these patients, with an increased risk of developing acute leukemia. This danger can be avoided by monitoring the lymphocytes of patients treated with hydroxyurea. Cytogenetic tests are important endpoints for monitoring the physiological effects of physical and chemical agents, including drugs. In this work, we assessed the genotoxicity of hydroxyurea in short-term cultures of lymphocytes from SCD patients. Hydroxyurea was not cytotoxic or genotoxic at the concentrations tested in the G2 phase of the cell cycle. These results support the use of hydroxyurea in the treatment of SCD, although further work is necessary to understand the effects of this drug in vivo
Keywords: Hidroxiuréia
Doença falciform
ISSN: 1415-4757
metadata.dc.rights: Acesso Aberto
Appears in Collections:Artigos Científicos - ICB

Files in This Item:
File Description SizeFormat 
Artigo_MutagenicityHydroxyureaLymphocytes.pdf57,7 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons